VYEPTI™ (eptinezumab-jjmr) 

Bullet Point
VYEPTIâ„¢ (eptinezumab-jjmr)
Lundbeck
100 mg/mL injection single dose vial
Item # 57182
NDC: 67386-0130-51
 90 Day Terms
Credit Card
Next Day Delivery

Reimbursement
Resources
VYEPTI is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults
 
Important Safety Information

CONTRAINDICATIONS
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.

WARNINGS AND PRECAUTIONS
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.